Erratum to: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study[Diabetologia(2015), DOI 10.1007/s00125-014-3344-3];Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Diabetologia

Volumn 57, Issue 11, 2014, Pages 2296-2303

  d’Emden, Michael C ^a,b   Jenkins, Alicia J ^c,d   Li, Liping ^c   Zannino, Diana ^c   Mann, Kristy P ^c   Best, James D ^d   Stuckey, Bronwyn G A ^e   Park, Kris ^f   Saltevo, Juha ^g   Keech, Anthony C ^c  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^f NEPEAN HOSPITAL   (Australia)

^g Central Finland Central Hospital   (Finland)

Author keywords

Adult; Cardiovascular prevention; Cardiovascular risk; Drug effects; Fibrate; Major clinical study; Non insulin dependent diabetes mellitus; Randomised controlled trial; Sex differences; Statin; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A; APOLIPOPROTEIN B; CALCIUM ANTAGONIST; CREATININE; DIURETIC AGENT; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG USE; DYSLIPIDEMIA; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; PATIENT COMPLIANCE; RHABDOMYOLYSIS; SEX DIFFERENCE; SMOKING; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84919880245     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3693-6     Document Type: Erratum

References (19)

1. World Health Organization (2008) World health statistics 2008. World Health Organization, Geneva, pp 1–110
2. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM (1999) Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med 341:217–225
3. Wang X, Magkos F, Mittendorfer B (2011) Sex differences in lipid and lipoprotein metabolism: it’s not just about sex hormones. J Clin Endocrinol Metab 96:885–893
4. FIELD Study Investigators, Keech A, Simes RJ, Barter P et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–1861
5. Rubins HB, Robins SJ, Collins D et al (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410–418
6. Frick MH, Elo O, Haapa K et al (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237–1245
7. BIP Study Group (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21–27
8. ACCORD Study Group (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:1563–1574
9. US Food and Drug Administration (2011) FDA drug safety communication: review update of Trilipix (fenofibric acid) and the ACCORD Lipid trial Silver Spring, MD: US FDA (updated 8 Dec 2011). Available from www.fda.gov/Drugs/DrugSafety/ucm278837.htm#sa, accessed 10 Jul 2014
10. Nilsson PM (2010) ACCORD and risk-factor control in type 2 diabetes. N Engl J Med 362:1628–1630
11. Simes J, Voysey M, O'Connell R et al (2010) A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PLoS One 5:e8580
12. Friedewald W, Levy R, Fredrickson D (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497
14. Collett D (2003) Modelling survival data in medical research, 2nd edn. Chapman & Hall, London
15. Krauss RM, Lindgren FT, Wingerd J, Bradley DD, Ramcharan S (1978) Effect of estrogens and progestins on high density lipoproteins. Lipids 14:113–118
16. Campos H, Walsh BW, Judge H, Sacks FM (1997) Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab 82:3955–3963
17. Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CDA, Gansevoort RT (2004) The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 256:1–14
18. Ginsberg HN (2011) Dyslipidemia in diabetes. The ACCORD Lipid Trial [slide set]. Loss of gender difference in primary outcome in the presence of dyslipidemia. p. 58. Silver Spring: US Food and Drug Administration. Available from www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM258121.pdf, accessed 10 Jul 2014
19. Scott R, O'Brien R, Fulcher G et al (2009) The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 32:493–498